TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2049258

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg daily
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 6395464

Group type: EXPERIMENTAL
Intervention: Piperacillin 150 mg/kg/day for 7.2 ± 2.75 days
Number of subjects: 41

Group type: COMPARATOR
Intervention: Carbenicillin 200 mg/kg/day for 7.5 ± 2.90 days
Number of subjects: 41
Study: 30621613

Group type: EXPERIMENTAL
Intervention: Lacunar infarction of SAI
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: Non-lacunar infarction of SAI
Number of subjects: 834

Group type: COMPARATOR
Intervention: MAIs
Number of subjects: 834
Study: 27907845

Group type: EXPERIMENTAL
Intervention: Increased maternal childhood adversities
Number of subjects: 1974

Group type: EXPERIMENTAL
Intervention: Higher household wealth
Number of subjects: 1974

Group type: EXPERIMENTAL
Intervention: Maternal education
Number of subjects: 1974

Group type: EXPERIMENTAL
Intervention: Social support, reporting HIV+, school enrollment of biologically-related children, overall health, reported alcohol use, and functional literacy
Number of subjects: 1974
Study: 27117972

Group type: EXPERIMENTAL
Intervention: Lutonix drug-coated balloon (DCB)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Uncoated balloon (PTA)
Number of subjects: 126
Study: 25148950

Group type: EXPERIMENTAL
Intervention: Cryotherapy (application of ice packs for 30 min)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Short‐wave diathermy (for 20 min)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 21788917

Group type: EXPERIMENTAL
Intervention: Endovascular coiling
Number of subjects: 413

Group type: COMPARATOR
Intervention: Neurosurgical clipping
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Greater clot clearance
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Higher baseline Hijdra score
Number of subjects: 413
Study: 19539078

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/20 mg
Number of subjects: 1128

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/40 mg
Number of subjects: 1128

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin
Number of subjects: 1128

Group type: COMPARATOR
Intervention: ezetimibe/simvastatin and atorvastatin
Number of subjects: 1128
Study: 16540080

Group type: EXPERIMENTAL
Intervention: Individual cognitive behaviour therapy (CBT) for 10 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group cognitive behaviour therapy (CBT) for 10 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control for 10 weeks
Number of subjects: 0
Study: 15152132

Group type: EXPERIMENTAL
Intervention: Cilostazol (100 mg twice daily)
Number of subjects: 705

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 705
Study: 12010934

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic agents (Class IA)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic agents (Class IC)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic agents (Class III)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: All drug classes
Number of subjects: 91
Study: 9577502

Group type: EXPERIMENTAL
Intervention: Two-dimensional MR digital subtraction angiography
Number of subjects: 23

Group type: COMPARATOR
Intervention: Two-dimensional time-of-flight (TOF) MR angiography
Number of subjects: 23
Study: 7641048

Group type: EXPERIMENTAL
Intervention: Topical sodium hyaluronate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (Healon buffer)
Number of subjects: 40
Study: 30608463

Group type: EXPERIMENTAL
Intervention: EMLA patch
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: TDP patch
Number of subjects: 154

Group type: COMPARATOR
Intervention: Lubricant gel patch (control)
Number of subjects: 154
Study: 29195623

Group type: EXPERIMENTAL
Intervention: Informative self-disclosure
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Apologetic self-disclosure
Number of subjects: 338

Group type: COMPARATOR
Intervention: No self-disclosure
Number of subjects: 338
Study: 26165012

Group type: EXPERIMENTAL
Intervention: Mild OSAHS Montelukast Treatment (MM) group - treated with leukotriene receptor antagonists (LTRAs)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Mild OSAHS Adenotonsillectomy Treatment (MAT) group - treated with adenotonsillectomy
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Mild OSAHS Montelukast Treatment (MM) group
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Severe OSAHS Montelukast Treatment (SM) group - treated with LTRAs
Number of subjects: 118

Group type: COMPARATOR
Intervention: Severe OSAHS Adenotonsillectomy Treatment (SAT) group - treated with adenotonsillectomy
Number of subjects: 118

Group type: COMPARATOR
Intervention: Mild OSAHS Adenotonsillectomy Treatment (MAT) group
Number of subjects: 118

Group type: COMPARATOR
Intervention: Severe OSAHS Adenotonsillectomy Treatment (SAT) group
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Severe OSAHS Montelukast Treatment (SM) group
Number of subjects: 118
Study: 23210546

Group type: EXPERIMENTAL
Intervention: Text message follow-up showing concern and reassurance
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no postprocedural communication)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 39
Study: 21463707

Group type: EXPERIMENTAL
Intervention: Face-to-face delivered exercise group (FtF)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Telephone delivered exercise group (Tel)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care group (UC)
Number of subjects: 200
Study: 19690991

Group type: EXPERIMENTAL
Intervention: Cytology + /HPV + (Group A, n=58)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Cytology-/HPV + (Group B, n=41)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Cytology + /HPV- (Group C, n=9)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Cytology-/HPV- (Group D, n=89)
Number of subjects: 197
Study: 16971641

Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis Bb12 supplementation
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 12652333

Group type: EXPERIMENTAL
Intervention: Bilateral subcutaneous hand injection of polyclonal human immunoglobulin G (HIgG) labelled with technetium‐99m
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Bilateral subcutaneous hand injection of polyclonal human immunoglobulin G (HIgG) labelled with indium‐111
Number of subjects: 37
Study: 11164063

Group type: EXPERIMENTAL
Intervention: CFS patients
Number of subjects: 277

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 277
Study: 9352953

Group type: EXPERIMENTAL
Intervention: Cisplatin and either mitomycin C and doxorubicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doxorubicin combination
Number of subjects: 0
Study: 7506171

Group type: EXPERIMENTAL
Intervention: nimesulide (100mg twice daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: diclofenac (50 mg/kg twice daily)
Number of subjects: 60
Study: 3548627

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (2.4 g as a single intravenous dose)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 94
Study: 31977840

Group type: EXPERIMENTAL
Intervention: HIV-tailored smoking cessation intervention
Number of subjects: 229

Group type: COMPARATOR
Intervention: Attention-controlled intervention
Number of subjects: 229
Study: 29198583

Group type: EXPERIMENTAL
Intervention: Closure (C) of the donor site
Number of subjects: 135

Group type: COMPARATOR
Intervention: Nonclosure (NC) of the donor site
Number of subjects: 135
Study: 27311846

Group type: EXPERIMENTAL
Intervention: 200 mg flurbiprofen
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 100 mg diclofenac sodium
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 20 mg tenoxicam
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study: 25297618

Group type: EXPERIMENTAL
Intervention: Enzyme-treated asparagus extract (ETAS)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 22365481

Group type: EXPERIMENTAL
Intervention: Home-based intensive exercise program supervised by a physical therapist
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care consisting of 1 session of instructions
Number of subjects: 30
Study: 20467920

Group type: EXPERIMENTAL
Intervention: MP plus thalidomide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MP plus bortezomib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: lenalidomide plus MP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: lenalidomide plus dexamethasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: high-dose dexamethasone plus thalidomide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: high-dose dexamethasone plus lenalidomide (RD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: high-dose dexamethasone plus bortezomib (VD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: bortezomib plus pegylated-liposomal-doxorubicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supportive care
Number of subjects: 0
Study: 19402836

Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 1006
Study: 15941887

Group type: EXPERIMENTAL
Intervention: Enzyme-hydrolyzed casein (EHC; MW <5000)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Protein-free diet
Number of subjects: 8
Study: 12749573

Group type: EXPERIMENTAL
Intervention: Brief Motivational Interviewing (BMI) training
Number of subjects: 22

Group type: COMPARATOR
Intervention: Untrained group (Control)
Number of subjects: 22
Study: 10333163

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 877

Group type: COMPARATOR
Intervention: Moclobemide
Number of subjects: 877
Study: 8541438

Group type: EXPERIMENTAL
Intervention: Methohexital
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 40
Study: 1682543

Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 586

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 586
Study: 7328226

Group type: EXPERIMENTAL
Intervention: Experimental treatment group
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 70

Group type: COMPARATOR
Intervention: Low-risk 'normal' control group
Number of subjects: 70
Study: 31541539

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29126290

Group type: EXPERIMENTAL
Intervention: Levothyroxine (LT4) treatment
Number of subjects: 366

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 366
Study: 26988766

Group type: EXPERIMENTAL
Intervention: Postexercise test (EXER) after standardized breakfast, endurance exercise, and 2 h fasting recovery
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Fasting test (FAST) 12 h after a standardized evening meal
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control test (CON) performed 3 h after a standardized breakfast
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: EXER compared to FAST
Number of subjects: 13

Group type: COMPARATOR
Intervention: FAST compared to CON
Number of subjects: 13

Group type: COMPARATOR
Intervention: Blood insulin levels at the start of EXER compared with CON and FAST
Number of subjects: 13

Group type: COMPARATOR
Intervention: Free fatty acid and cortisol levels at the start of EXER compared with CON and FAST
Number of subjects: 13
Study: 23148449

Group type: COMPARATOR
Intervention: Increasing price trend
Number of subjects: 30

Group type: COMPARATOR
Intervention: Decreasing price trend
Number of subjects: 30
Study: 22980723

Group type: EXPERIMENTAL
Intervention: Biaxial small-incision torsional phacoemulsification
Number of subjects: 70

Group type: COMPARATOR
Intervention: Biaxial small-incision longitudinal phacoemulsification
Number of subjects: 70
Study: 20345390

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (target hemoglobin 9.5-11.0 g/dL and 11.5-13.0 g/dL)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 17030095

Group type: EXPERIMENTAL
Intervention: Pain-reducing ointment (placebo)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Neutral ointment (control)
Number of subjects: 96
Study: 15980714

Group type: EXPERIMENTAL
Intervention: 1 mm intracoronal barrier of Triage glass ionomer
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2 mm Triage barrier
Number of subjects: 30

Group type: COMPARATOR
Intervention: No barrier (Control)
Number of subjects: 30
Study: 11838886

Group type: EXPERIMENTAL
Intervention: Combination low-fat/low-energy diet
Number of subjects: 86

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 86

Group type: COMPARATOR
Intervention: Low-energy diet
Number of subjects: 86
Study: 10404809

Group type: EXPERIMENTAL
Intervention: Intranasal E2 (300 microg/day)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Intranasal E2 (100, 200, 300, and 400 microg/day)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Oral E2 (1 and 2 mg/day)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study: 7579507

Group type: EXPERIMENTAL
Intervention: Systematic random sampling (SRS) with 50 nuclei (SRS-50)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Systematic random sampling (SRS) with 100 nuclei (SRS-100)
Number of subjects: 191

Group type: COMPARATOR
Intervention: At convenience sampling (ACS) with 50 nuclei (ACS-50)
Number of subjects: 191
Study: 2404636

Group type: COMPARATOR
Intervention: Verapamil (120 mg t.i.d.)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Nicardipine (30 mg t.i.d.)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Nisoldipine (10 mg b.i.d.)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Nisoldipine and digoxin (in congestive heart failure)
Number of subjects: 66
Study: 7043751

Group type: EXPERIMENTAL
Intervention: Sulfadoxine 20 mg/kg and pyrimethamine 1.0 mg/kg (Group 1)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Sulfadoxine 30 mg/kg and pyrimethamine 1.5 mg/kg (Group 2)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Quinine 10 mg/kg 8 hourly for 5 days plus sulfadoxine 20 mg/kg and pyrimethamine 1.0 mg/kg (Group 3)
Number of subjects: 68
Study: 29339470

Group type: EXPERIMENTAL
Intervention: Voucher covering the naturalization application fee
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral nudges for low-income immigrants
Number of subjects: 0
Study: 27327217

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24360749

Group type: EXPERIMENTAL
Intervention: Walnut-enriched diet (43g/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Western-type (control) diet
Number of subjects: 40
Study: 24321091

Group type: EXPERIMENTAL
Intervention: HIV‐1 DNA vaccine at months 0, 1 and 3; HIV‐1 MVA vaccine at months 9 and 21
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Educational sessions
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Pre-screening workshops
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Initial screenings
Number of subjects: 79
Study: 20638452

Group type: EXPERIMENTAL
Intervention: Intranasal vaccine
Number of subjects: 2389

Group type: COMPARATOR
Intervention: Injectable vaccine
Number of subjects: 2389

Group type: EXPERIMENTAL
Intervention: Study interventions (enhanced advertising, choice of vaccine type, and incentive)
Number of subjects: 2389

Group type: EXPERIMENTAL
Intervention: Intentional vaccine choice
Number of subjects: 2389
Study: 18995180

Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 0
Study: 16386854

Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 68
Study: 12504040

Group type: EXPERIMENTAL
Intervention: Concomitant radiochemotherapy (Arm B: 70 Gy in 35 fractions with three cycles of a 4-day regimen containing carboplatin and 5-fluorouracil)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Concomitant radiochemotherapy (Arm B)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Radiotherapy alone (Arm A: 70 Gy in 35 fractions)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Radiotherapy alone (Arm A)
Number of subjects: 226
Study: 10617952

Group type: EXPERIMENTAL
Intervention: High iron bioavailability diet (14.4 mg nonheme Fe/d, 1.8 mg heme Fe/d)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Low iron bioavailability diet (15.3 mg nonheme Fe/d, 0.1 mg heme Fe/d)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Comparison of high and low bioavailability diets
Number of subjects: 31

Group type: COMPARATOR
Intervention: Low bioavailability diet
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Erythrocyte incorporation of absorbed iron
Number of subjects: 31
Study: 9097256

Group type: EXPERIMENTAL
Intervention: NMS-assisted arm ergometry (Group I, n = 12)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: NMS-assisted arm ergometry followed by arm ergometry alone (Group II, n = 11)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Arm ergometry alone (Group III, n = 11)
Number of subjects: 34

Group type: COMPARATOR
Intervention: NMS-assisted arm ergometry (Group I) vs Arm ergometry alone (Group III)
Number of subjects: 34

Group type: COMPARATOR
Intervention: NMS-assisted arm ergometry followed by arm ergometry alone (Group II) vs Arm ergometry alone (Group III)
Number of subjects: 34
Study: 1397769

Group type: EXPERIMENTAL
Intervention: Digital noise suppression algorithm (INTEL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nucleus cochlear implant users
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normally hearing adults
Number of subjects: 20
Study: 3859954

Group type: EXPERIMENTAL
Intervention: 0.4 mg PGE2 gel placed retroamnially by means of a balloon catheter
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.4 mg PGE2 gel applied endocervically
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.5 mg PGE2 gel applied endocervically
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.5 mg PGE2 given pericervically through a portio adapter
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3 mg PGE2 placed intravaginally in form of a single vaginal tablet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (only vaginal examination)
Number of subjects: 0
Study: 30113178

Group type: EXPERIMENTAL
Intervention: Worksite health promotion intervention
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 202
Study: 30511680

Group type: EXPERIMENTAL
Intervention: APD machine made in China
Number of subjects: 260

Group type: COMPARATOR
Intervention: Imported APD machine
Number of subjects: 260
Study: 27583475

Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional lifestyle advice (control)
Number of subjects: 27
Study: 24779483

Group type: EXPERIMENTAL
Intervention: Information about the association between viral load and contagiousness (low viral load condition)
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Information about the association between viral load and contagiousness (high viral load condition)
Number of subjects: 752

Group type: COMPARATOR
Intervention: No information about the association between viral load and contagiousness (control group)
Number of subjects: 752
Study: 23519393

Group type: EXPERIMENTAL
Intervention: Cough Quality-of-Life Questionnaire (CQLQ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 0
Study: 20452468

Group type: EXPERIMENTAL
Intervention: Mild exercise
Number of subjects: 34
Study: 18787893

Group type: EXPERIMENTAL
Intervention: Naproxen 250 mg BD
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 15696558

Group type: EXPERIMENTAL
Intervention: High exercise adherence
Number of subjects: 134
Study: 12848634

Group type: EXPERIMENTAL
Intervention: Valdecoxib (40 mg b.d.)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg b.d.)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study: 10342404

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8663954

Group type: EXPERIMENTAL
Intervention: Cutaneous-only excisions
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cutaneous-vestibular excisions
Number of subjects: 40
Study: 1992102

Group type: EXPERIMENTAL
Intervention: Dapsone 200 mg daily
Number of subjects: 7
Study: 6744646

Group type: EXPERIMENTAL
Intervention: Noradrenaline (alpha‐1 adrenoceptor agonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salbutamol (beta 2‐adrenoceptor agonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects (not specified)
Number of subjects: 0
Study: 30891886

Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 720

Group type: COMPARATOR
Intervention: Insulin glargine U100
Number of subjects: 720
Study: 30212253

Group type: COMPARATOR
Intervention: Standard protein diet (1.1 g·kg‐1·day‐1, 39% fat)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Higher protein diet (2.1 g·kg‐1·day‐1, 23% fat)
Number of subjects: 17
Study: 27069104

Group type: EXPERIMENTAL
Intervention: Paclitaxel-Eluting Balloon (PEB)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Everolimus-Eluting Stents (EES)
Number of subjects: 136
Study: 24906174

Group type: EXPERIMENTAL
Intervention: Lercanidipine 20 mg + Enalapril 20 mg
Number of subjects: 1039

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1039

Group type: EXPERIMENTAL
Intervention: Lercanidipine (10 or 20 mg) or Enalapril (10 or 20 mg)
Number of subjects: 1039
Study: 21293245

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) and observation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stereotactic radiosurgery (SRS) and whole brain radiation therapy
Number of subjects: 0
Study: 20559273

Group type: EXPERIMENTAL
Intervention: Glycine (0.1g) and Limontar (0.25g) 3 times a day
Number of subjects: 112

Group type: COMPARATOR
Intervention: Basic therapy (treatment of glycemia, vasoactive drugs)
Number of subjects: 112
Study: 22281182

Group type: EXPERIMENTAL
Intervention: Miglustat 200 mg t.i.d. for 8 days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo for 8 days
Number of subjects: 11